Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 15/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912319 | 1.00 | PTGFR (0.38) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL3009597 | 1.00 | PTGFR (0.38) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL14352897 | 1.00 | PTGFR (0.38) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL14352819 | 0.90 | PTGFR (0.37) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL14352820 | 0.90 | PTGFR (0.37) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL15106761 | 0.90 | PTGFR (0.44) | PTGFRPTGER3TBXA2RMEN1ALDH1A1 | |
| SCHEMBL15106763 | 0.90 | PTGFR (0.44) | PTGFRPTGER3TBXA2RMEN1ALDH1A1 | |
| SCHEMBL8633845 | 0.90 | PTGFR (0.37) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL8414060 | 0.90 | PTGFR (0.37) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL11916721 | 0.89 | MEN1 (0.34) | PTGER2MEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304562-B2 | Method for preparing prostaglandin derivative | SUCAMPO AG (CH) | 2012-11-06 | — | — | US | claimed |
| US-20070244333-A1 | Method for preparing prostaglandin derivative | R-TECH UENO, LTD. (JP) | 2007-10-18 | — | — | US | claimed |
| EP-1981867-B1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | R-TECH UENO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-2726472-B1 | METHOD FOR PREPARING A FATTY ACID DERIVATIVE | R-TECH UENO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-9242950-B2 | Method for preparing a fatty acid derivative | R-TECH UENO, LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| EP-2735566-A1 | Method for preparing prostaglandin derivative | R-Tech Ueno, Ltd. (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-8389748-B2 | Method for preparing prostaglandin derivative | SUCAMPO AG (CH) | 2013-03-05 | — | — | US | disclosed |
| US-20130005995-A1 | METHOD FOR PREPARING A FATTY ACID DERIVATIVE | SUCAMPO AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-8304562-B2 | Method for preparing prostaglandin derivative | SUCAMPO AG (CH) | 2012-11-06 | — | — | US | disclosed |
| US-8236969-B2 | Method for preparing prostaglandin derivative | SUCAMPO AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100274032-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | SUCAMPO AG (CH) | 2010-10-28 | — | — | US | disclosed |
| US-7812182-B2 | Benzyl 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydro cyclopenta[b]pyran-5-yl]heptanate | SUCAMPO AG (CH) | 2010-10-12 | — | — | US | disclosed |
| US-20100204489-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | SUCAMPO AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204491-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | SUCAMPO AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20070244333-A1 | Method for preparing prostaglandin derivative | R-TECH UENO, LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274032-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | PTGS1, PTGER1, PTGS2 | PTGFR 18/4885PTGER1 2/4885PTGER2 7/4885 |
| US-20070244333-A1 | Method for preparing prostaglandin derivative | PTGS1, PTGER1, PTGS2 | PTGFR 18/4885PTGER1 2/4885PTGER2 7/4885 |
| US-20130005995-A1 | METHOD FOR PREPARING A FATTY ACID DERIVATIVE | ALOX12, ELOVL1, ALOX5 | PTGFR 2590/4885PTGER1 276/4885PTGER2 304/4885 |
| US-20100204489-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | PTGS1, PTGER1, PTGS2 | PTGFR 18/4885PTGER1 2/4885PTGER2 7/4885 |
| US-20100204491-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | PTGS1, PTGER1, PTGS2 | PTGFR 18/4885PTGER1 2/4885PTGER2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.